Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program

August 20, 2018 at 8:30 AM EDT
-- 10 academic scholarships awarded to students diagnosed with Duchenne muscular dystrophy as they pursue their post-secondary education this fall --

CAMBRIDGE, Mass., Aug. 20, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, announced today the recipients of its Route 79, The Duchenne Scholarship Program. Launched in March 2018, the Scholarship Program was created to recognize exceptional individuals dedicated to pursuing their post-secondary education. Ten recipients were chosen by an independent selection committee comprised of Duchenne community members based on each applicant’s community involvement and a personal essayi. Each of the 10 students will receive scholarships of up to $10,000.

“On behalf of Sarepta and the members of the selection committee, congratulations to our 10 scholarship recipients. We are honored to recognize your remarkable achievements,” said Doug Ingram, Sarepta’s president and chief executive officer. “The selection process was challenging given the impressive dedication and effort of all of the applicants and the quality of writing, which far exceeded our lofty expectations. To all applicants, we applaud your tremendous talent and wish you continued success on your journey in higher education. Finally, I would like to express my appreciation to the selection committee, the members of which gave so generously of their time in reviewing the applications and essays.” 

A member of the independent, blinded selection committee shared, “Reading through the essays and applications was really inspiring. As a father of a young boy with Duchenne, I'm filled with hope for his future.”

2018 Named Recipients - Route 79, The Duchenne Scholarship Program

Name  Academic Institution
Porter Aydelotte  Saddleback College
Alex Carlson  University of Northern Iowa
Liam Chambers Virginia Commonwealth University
Jerome Davis  University of California - Los Angeles
Robert Ivey Oakland University
Kushal Kuchibhotla  University of California-Irvine
William Ma Ohio State University
Cody Schoppe Temple College
Jordan Wayne Grand View University
Jack Wolf  University of Akron

iNo consideration was given to whether or not an applicant was previously, is currently, or expects to be in the future, undergoing treatment with a Sarepta product or investigational product.

About Route 79, The Duchenne Scholarship Program
Route 79, The Duchenne Scholarship Program is designed to help students diagnosed with Duchenne muscular dystrophy (Duchenne) pursue their post-high school educational goals. There are 79 exons in the dystrophin gene impacted by Duchenne, and the route traveled by every person with Duchenne is distinct. Sarepta’s goal through this program is to acknowledge and support ten individuals with Duchenne who are mapping out their future via educational pursuits.

Scholarships of up to $10,000 are awarded to ten scholarship recipients.

About Sarepta Therapeutics
Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates. For more information, please visit www.sarepta.com.

Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us. 

Source: Sarepta Therapeutics, Inc.

Media and Investors:
Sarepta Therapeutics, Inc.
Ian Estepan, 617-274-4052
iestepan@sarepta.com
or
W2O Group
Rachel Hutman, 301-801-5540
rhutman@w2ogroup.com

Primary Logo

 

Source: Sarepta Therapeutics, Inc.